Project Details
Projekt Print View

Platelet-monocyte interactions in Systemic Lupus Erythematosus

Subject Area Hematology, Oncology
Term from 2019 to 2022
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 429657170
 
Final Report Year 2023

Final Report Abstract

I have shown that platelet:monocyte interaction shapes the monocyte transcriptome and phenotype in thromboinflammation. Consistent with a proinflammatory platelet effector role, MPA were increased in patients with COVID-19. RNA-Seq revealed a thromboinflammatory monocyte transcriptome upon incubation with platelets. Monocytes aggregated to platelets expressed higher CD40 and tissue factor than monocytes without platelets (p<0.05 for each). Inhibition with P-selectin (85% reduction) and PSGL1 (87% reduction) led to a robust decrease in MPA. P2Y12 and PAR1 inhibition lowered MPA formation (30% and 21% reduction, p<0.05, respectively) and decreased monocyte CD40 and TF expression while GP IIb/IIIa and COX1 inhibition had no effect. Pretreatment of platelets with P2Y12 inhibitors reduced the expression of platelet-mediated monocyte transcription of proinflammatory SOCS3 and OSM. While the COVID-19 pandemic temporarily interrupted my main research project, the finding that infected patients developed a substantial risk of thromboembolic adverse events fueled additional scientific projects in which I critically contributed to analyzing the effector role of platelets on endothelial cells. Here, we could demonstrate that COVID-19 platelets are proinflammatory, exhibit upregulation of inflammatory pathways, and induce endothelial dysfunction.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung